Form 4 for BIAF bioAffinity Technologies, Inc.
Accepted 2023-07-06 00:00:00 ET · period of report 2023-01-01 · accession 0001493152-23-023817 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-07-06 | 2023-01-01+ | BIAF | Zannes Maria | Pres, CEO, Dir | A - Grant | $1.95 | +54.6K | 69.9K | +356% | +$106.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-01 | A | A | 10,245 | $1.83 | 116,238 | D | — | — | (F4) Represents a grant from the Issuer to Ms. Zannes of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. |
| 2 | Common | Common Stock | 2023-06-06 | A | A | 26,178 | $1.91 | 105,993 | D | — | — | (F3) Represents a grant of 26,178 shares of Common Stock to Ms. Zannes on June 6, 2023 pursuant to Unanimous Written Consent of the Board of Directors of the Issuer dated November 17, 2022. |
| 3 | Common | Common Stock | 2023-04-15 | A | A | 9,920 | $1.89 | 79,815 | D | — | — | (F2) Represents a grant from the Issuer to Ms. Zannes of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Ms. Zannes continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. |
| 4 | Common | Common Stock | 2023-01-01 | A | A | 8,227 | $2.28 | 69,895 | D | — | — | (F1) Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Ms. Zannes of 8,227 restricted shares of common stock, par value $0.007 (the "Common Stock"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. |